Site icon fundsforNGOs

CFPs: Breakthrough T1D Small Grant Programme (United Kingdom)

US: Capacity Building Grant for Small Nonprofits ($20,000 Unrestricted Grant)

Deadline: 13-Apr-2026

The Breakthrough T1D Small Grant Programme provides funding for early career researchers in the UK to pursue innovative projects on type 1 diabetes. Grants of up to £20,000 for basic research and £30,000 for clinical research support exploratory studies that can inform future research, clinical practice, and patient-focused outcomes.

Overview

The programme aims to:

Funding & Duration

Eligibility

Why It Matters

The programme builds research capacity, supports innovative type 1 diabetes studies, and helps early career investigators generate impactful findings that can improve patient care and advance scientific understanding.

How to Apply

  1. Confirm eligibility as an early career researcher in the UK
  2. Prepare a research proposal with a clear impact pathway
  3. Ensure project aligns with type 1 diabetes innovation and patient relevance
  4. Submit the application according to programme guidelines

FAQs

  1. Who can apply?
    Early career researchers in the UK, including basic scientists, clinicians, and healthcare professionals.
  2. What funding is available?
    Up to £20,000 for basic research, up to £30,000 for clinical research.
  3. What is the maximum project duration?
    12 months.
  4. Can existing grant holders apply?
    Only if they haven’t held a grant over £100,000 as principal investigator (excluding personal fellowships).
  5. Where must the research be conducted?
    Within the UK.
  6. Are patient perspectives required?
    Yes, projects should incorporate the needs and perspectives of people living with type 1 diabetes.
  7. Can this funding supplement other grants?
    Generally no, unless it’s a well-justified sub-study.

Conclusion

The Breakthrough T1D Small Grant Programme empowers UK early career researchers to pursue innovative, impactful studies in type 1 diabetes, supporting the next generation of research leaders and advancing understanding and management of the disease.

For more information, visit Breakthrough T1D.

Exit mobile version